Expands access to the psychedelic-assisted therapy pilot program in Connecticut.
The bill expands access to the psychedelic-assisted therapy pilot program in Connecticut, effective July 1, 2026. It defines "MDMA" and "psilocybin," and establishes criteria for "qualified patients," including veterans, retired first responders, and residents of the state. The pilot program will be administered by a medical school selected by the institutional review board.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
Analyze for Free
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.